Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital... Read More

Strong organic revenue growth 1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed to earnings Operating income 2 grew by 13% at constant currency, further driving margin expansion Stable reported operating income and 20% increase in reported net income 3 Operating cash flow improved strongly by 75%, net... Read More

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registry Paves way for advances in precision kidney disease care, novel therapies, and diagnostics BAD HOMBURG, Germany , July 31, 2025 /PRNewswire/... Read More

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico , 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany , July 3, 2025 /PRNewswire/ -- Fresenius Medical Care... Read More

FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plans Profitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income 1 margins FME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027... Read More

Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltration therapy to dialysis patients Introducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategy BAD HOMBURG, Germany , June 4, 2025 /PRNewswire/ -- Fresenius... Read More

Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient outcomes. Top Abstract recognition for "Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort," presented in the "Dialysis" category. CONVINCE trial... Read More

Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growth In 2024, organic revenue growth 1 was 4 percent, and operating income increased by 18 percent on an... Read More

Strong organic revenue growth 1 of 5% driven by Care Enablement and Care Delivery Stable U.S. same market treatment development despite impact from a severe flu season FME25 savings of EUR 68 million contributed to earnings Operating income 2 grew 11% at constant currency resulting in margin expansion Reported operating income grew by 35% and reported net income 3 by 113% Net leverage ratio further improved to 2.8x and FY... Read More

In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholders Fresenius Medical Care delivered 18% operating income growth on an outlook base in 2024 Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprint BAD HOMBURG, Germany , March 13, 2025 /PRNewswire/ --... Read More

Organic revenue growth 1 of 4% driven by Care Enablement and Care Delivery Underlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year Accumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 million With 18% operating income 2 growth top end of the 2024 outlook range reached Reported operating income grew by 2%, reported net... Read More

Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of... Read More

Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and Europe The company recorded progress towards its sustainability targets Sustainability is one of the essential drivers for future BAD HOMBURG, Germany , Dec. 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has been recognized... Read More

BAD HOMBURG, Germany , Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, will return to the top tier of the German Stock Index, the DAX 40, as of December 27, 2024 . The index represents the performance of the 40 largest publicly traded companies listed on the Frankfurt Stock Exchange and accounts for around 80 percent of the... Read More

Strategic Relationship: Agreement expands access to ECMO solutions for hospitals, health systems and patients in the U.S. nationwide. Wide Reach: 4,350+ Premier member hospitals and health systems in the U.S. can leverage pre-negotiated terms and pricing on the Novalung System for ECMO. Commitment to Quality Care: Reinforces company's commitment to supporting healthcare providers in their efforts to deliver high-quality... Read More

Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income 1 and operating income margin 1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income 1 growth outlook with 16-18%... Read More

A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions. Nearly 75 abstracts... Read More

Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis... Read More

Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income 1 and operating income margin 1 increase driven by Care Enablement Additional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target range Further divestitures closed as execution of portfolio optimization program continues Net financial debt and net leverage... Read More

Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO 2 emissions footprint Company enacts five virtual power purchase agreements for around 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. Energy farms scheduled to go into operation in 2024 and 2025 Important milestone for strategic sustainability goal to achieve... Read More

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress Solid deleveraging prospects BAD HOMBURG, Germany , May 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the... Read More

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence Company-wide experts highlight robust anonymized dialysis database CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented BAD HOMBURG, Germany , May 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of... Read More

Today's Annual General Meeting was the first one following the change in legal form completed in November 2023 Shareholders voted in favor of the proposed dividend of 1.19 euros , representing an increase of around 6 percent compared to the previous year New compensation system for Management Board approved Ambitious growth targets for 2024 confirmed BAD HOMBURG, Germany , May 16, 2024 /PRNewswire/ -- Fresenius Medical Care... Read More

Solid revenue 1 growth of 4% driven by both segments Care Delivery and Care Enablement Operating income 1 margin improved in both segments Care Enablement delivered strong sequential margin improvement with significant progress towards the 2025 target margin band Execution of transformation continues at pace, contributing additional FME25 savings of EUR 52 million Portfolio optimization program progresses in Care Delivery... Read More

Fresenius Medical Care delivers on commitments during a year of fundamental transformation Progress towards sustainability goals in key areas: patient satisfaction, diversity in management, climate target roadmap BAD HOMBURG, Germany , March 22, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of... Read More

For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digital learning elements with real-life training on the Fresenius Medical Care Continuous Kidney Replacement Therapy system This learning experience reinforces initial training, a supplement to support new staff amidst the high... Read More

Effective June 1 , the Legal, Compliance, and Human Resources functions will be combined in a new Management Board role Jörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectors BAD HOMBURG, Germany , March 13, 2024 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of... Read More

Divestment of assets includes four separate country transactions to DaVita Inc. for USD 300 million Transactions further reduce the Company`s clinic footprint in Latin America , following the exit from Argentina at the end of 2023 Expected to close throughout 2024 Proceeds to be used to reduce debt BAD HOMBURG, Germany , March 5, 2024 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and... Read More

Revenue growth of 5% in 2023 driven by favorable business development Operating income 1 growth of 15% exceeding top end of outlook range, due to business growth, FME25 savings ahead of plan and contributions from the Tricare settlement Successful execution on turnaround plan resulting in significant labor productivity improvements in Care Delivery and positive pricing in Care Enablement Several key divestments announced as... Read More

Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System. This will enable Fresenius Medical Care to offer the industry-leading, high-volume hemodiafiltration (Hv-HDF) dialysis therapy – already widely used in Europe – for people living with kidney diseases in the U.S. The 510(k) clearance allows the start of clinical evaluations and... Read More

BAD HOMBURG, Germany , Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26 , the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial... Read More

Divestments in 2023 are important milestones of the Company's execution against its Portfolio Optimization which are part of the set strategic aspirations Delivers on commitment to improve leverage ratio by allocating expected EUR 0.5 billion proceeds from divestments to deleverage BAD HOMBURG, Germany , Jan. 8, 2024 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for... Read More

Change of legal form simplifies the corporate governance structure as a German stock corporation (Aktiengesellschaft) The composition of the Management Board remains as before; the new Supervisory Board assumes office with immediate effect Business model and strategic plan remain strong and continue to translate into improved operating performance BAD HOMBURG, Germany , Nov. 30, 2023 /PRNewswire/ -- Fresenius Medical Care ,... Read More

WALTHAM, Mass. , Nov. 21, 2023 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases, resolved a legal dispute with the U.S. government, for accounts receivable in legal dispute, and entered into a final and legally binding settlement agreement today, whereby the company will receive a payment from the U.S. government. Fresenius Medical Care had... Read More

Continued solid organic growth in Care Enablement and Care Delivery including sequentially stable same market treatment growth in the U.S. Successful execution on turnaround plan driving productivity improvements in Care Delivery and pricing in Care Enablement FME25 transformation savings fully on track Continued execution on portfolio optimization strategy FY 2023 earnings outlook raised WALTHAM, Mass. , Nov. 1, 2023... Read More

WALTHAM, Mass. , Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment. Cordola will start on January 1, 2024 , as Chief Executive Officer of Care Delivery. He will be based in Waltham, Massachusetts . Craig Cordola will... Read More

Company-wide research offers novel pathways for enhancing kidney patient care using data-driven insights and real-world evidence WALTHAM, Mass. , Oct. 31, 2023 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of over 60 company-affiliated research abstracts at the American Society of Nephrology's (ASN) Kidney... Read More

Powerful Cloud-Based Data Asset to Drive Improvements in Care Quality and Patient Outcomes as the Largest Multinational, Longitudinal Database of its kind Achievement Part of Company's Long-Term AI Strategy and Ongoing Digital Transformation Efforts WALTHAM, Mass. , Oct. 26, 2023 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases, today announced... Read More

KINSTON, N.C. , Oct. 11, 2023 /PRNewswire/ -- Capital Square , one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer of multifamily communities, announced today the sale of a medical building in Kinston, North Carolina . The property was owned by a group of DST investors who realized 147.63% total return, or a 7.15% annualized return, from their 1031 exchange investment.*... Read More

WALTHAM, Mass. , Aug. 23, 2023 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for Versi ® HD with GuideMe Software, a completely reinvented self-guided interface for... Read More

The new partnership delivers care for hemodialysis patients at their local hospital, who previously had to travel nearly 100 miles for care, eliminating the need to be transferred to a more urban hospital. WALTHAM, Mass. , Aug. 9, 2023 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and... Read More

Organic growth accelerated in the second quarter in Care Enablement and Care Delivery including sequentially stable treatment volumes in the U.S. Execution on turnaround plan translates into visible productivity improvements in Care Delivery achieving a Q2 margin at the lower end of the 2025 target margin band Savings resulting from FME25 transformation program fully on track Successful execution on portfolio optimization... Read More

Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal form Several advantages including faster and more agile decision-making Michael Sen elected as Chair of new Supervisory Board Conversion expected to be completed by the end of 2023 WALTHAM, Mass. , July 14, 2023 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases,... Read More

WALTHAM, Mass. , July 10, 2023 /PRNewswire/ -- Fresenius Medical Care , the world's leading provider of products and services for individuals with renal diseases has appointed Martin Fischer (46) as Chief Financial Officer as of October 1, 2023 . He will succeed Helen Giza who was appointed as Chief Executive Officer and Chair of the Management Board in December 2022 and continues to serve as acting Chief Financial Officer,... Read More

First-of-its-kind training program prepares dialysis patients for home therapy WALTHAM, Mass. , March 22, 2023 /PRNewswire/ -- Since the new year began, Ms. Bailey-Wilson has been counting down the days until spring rolls around. Bailey-Wilson's family is planning to embark on a seven-day cruise, and she has already blocked off the week from her full-time job as a supervisor at a call center. However, there's one important... Read More

Fresenius Kidney Care Funds National Accreditation and Accelerator Program for More Than 40 Nonprofit Medically Tailored Food and Nutrition Service Providers Across the U.S. With $150,000 Donation WALTHAM, Mass. , March 13, 2023 /PRNewswire/ -- Fresenius Kidney Care , the nation's leader in kidney care services and education, renewed its support for the Food Is Medicine Coalition (FIMC) to help those living with severe... Read More

Partnership Supports the Clubs' Healthy Habits Program and National Days of Advocacy Event WALTHAM, Mass. , March 6, 2023 /PRNewswire/ -- Fresenius Kidney Care , the nation's leader in kidney care services and education, is donating $275,000 to Boys & Girls Clubs of America (BGCA) to educate youth across the country on kidney... Read More

WALTHAM, Mass. , Jan. 20, 2023 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has taken the Zero Health Gaps Pledge at the World Economic Forum in Davos, Switzerland . The Zero Health Gaps Pledge is part of the Global Health Equity Network (GHEN), which brings together key stakeholders from the public and private sectors to advance a... Read More

Grant allows partners to expand kidney disease education project to rural Mississippi patients FMCNA implementing virtual reality education in other states WALTHAM, Mass. , Jan. 5, 2023 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading renal care provider, has won a major grant from the Mississippi Department of Health's (DOH) Office of Rural Health and Primary Care to expand kidney education... Read More